NuCana (NASDAQ:NCNA) Stock Price Down 2.4% – What’s Next?

NuCana PLC Sponsored ADR (NASDAQ:NCNA) shares traded down 2.4% during trading on Thursday . The stock traded as low as $1.60 and last traded at $1.60. 26,135 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 48,707 shares. The stock had previously closed at $1.64.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

NuCana Trading Down 3.1%

The stock has a market capitalization of $6.45 million, a P/E ratio of -0.52 and a beta of 2.18. The business’s fifty day simple moving average is $2.02 and its two-hundred day simple moving average is $2.40.

NuCana (NASDAQ:NCNA) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $1.39.

Institutional Trading of NuCana

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC increased its position in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the quarter. FNY Investment Advisers LLC owned approximately 33.33% of NuCana worth $36,000 at the end of the most recent quarter. 44.00% of the stock is currently owned by hedge funds and other institutional investors.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.